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The incidence of hepatitis B (HB) recurrence after a liver transplantation has been reduced by prophylaxis with hepatitis B
immunoglobulin (HBIG) and lamivudine. However, the long-term incidence of recurrence is 10%, and the factors associated
with HB recurrence are unclear. This study analyzed the factors associated with HB recurrence in 203 recipients who
underwent liver transplantation for HB in 3 major centers in Korea over 4 years. Eighty-ﬁve patients (41.9%) had a
hepatocellular carcinoma (HCC). Preoperative active virus replicators with the HBeAg() (46.8%) and/or hepatitis B virus
DNA() (39.4%) were observed in 136 patients (67.0%). The HB prophylaxis consisted of either HBIG monotherapy (n  95,
HBIG group) or combination therapy with lamivudine (n  108, combination group). HB recurrence was deﬁned as the
appearance of the HBsAg. The follow-up period was 28.3  13.1 months (mean  SD). HB recurred in 21 patients (10.3%)
after transplantation. The time from transplantation to recurrence was 16.3  9.4 months. Pre-LT DNA positivity was more
prevalent in HBIG group (55.8%) than in the combination group (39.8%) (P 0.015). However, the incidence of HB recurrence
was similar in the HBIG (6.3%) and combination group (13.8%), as well as between the active replicators (12.5%) and
nonreplicators (4.1%) (P  0.05). There was a far higher incidence of HB recurrence in patients receiving corticosteroid pulse
therapy (21.0% vs. 7.9%), patients who experienced HCC recurrence (31.3% vs. 8.6%), and patients receiving chemotherapy
to prevent HCC recurrence (25.0% vs. 4.4%) (P  0.05). The cumulative corticosteroid dose was higher in patients who
experienced recurrence of HB (P  0.002). Multivariable analysis conﬁrmed the effect of the cumulative corticosteroid dose
and chemotherapy to be risk factors. Liver transplantation for HB is safe, with low recurrence rates if adequate prophylaxis is
used. However, the cumulative corticosteroid dose and the chemotherapy used for HCC were risk factors for HB recurrence,
so careful monitoring for HB recurrence is needed in these patients. Liver Transpl 13:451-458, 2007. © 2007 AASLD.
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The outcome of liver transplantation (LT) for hepatitis B
virus (HBV)-related liver diseases was dismal before the
advent of an effective means for preventing the virtually
universal reinfection of the graft. Reinfection was fol-
lowed by progressive destruction by recurrent hepati-
tis. This led to quick graft failure. HBV-related liver
disease was once considered to be a contraindication
for LT. However, over the last 15 years, there have been
major advances in the management of transplant can-
didates with hepatitis B (HB). The long-term use of
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hepatitis B immunoglobulin (HBIG) therapy and the
introduction of new antiviral agents, such as lamivu-
dine, against HBV infections have been major break-
throughs.1,2 Today, the results of LT for HBV-related
liver disease are similar to that of patients receiving
transplants for other indications. Nevertheless, 10% of
LT patients with underlying HB experience a recur-
rence.3-5 The factors associated with HB recurrence are
unclear.
This study examined 203 patients who underwent LT
for HBV-related liver disease in 3 major centers in Ko-
rea, with the aim of evaluating the risk factors associ-
ated with HB recurrence and the safety of the HB pro-
phylactic protocol after LT in the era of HBIG and
lamivudine.
METHODS
Between January 1999 and December 2002, a total of
203 adult patients (age 18 years or older) who under-
went LT for HBV-related liver disease and were followed
up for at least 6 months were enrolled onto this study.
The mean interval between registration to the Korean
Network for Organ Sharing and the transplantation was
5.4  7.9 months (mean  SD, range, 0-64.4 months).
Table 1 summarizes the patients’ data at the time of
transplantation. There were 151 cases of living donor
LT and 56 cases of deceased donor LT, including 4
cases of retransplantation. A hepatitis C virus coinfec-
tion was found in 3 cases (1.5%). Eighty-ﬁve patients
(41.9%) were associated with a hepatocellular carci-
noma (HCC). A replicative HBV infection was deﬁned as
the presence of the hepatitis e antigen (HBeAg) and/or
HBV DNA in serum. The HBV DNA was tested by means
of a nonampliﬁed hybrid capture assay with a
branched-chain DNA assay (Greencross, Korea). The
detection threshold for the DNA was 105 copies/mL.
One hundred thirty-six patients (67.0%) were pre-LT
active replicators at the time of the transplantation.
HBeAg positivity and HBV DNA positivity was noted in
95 (46.8%) and 80 patients (39.4%), respectively. There
were 92 patients (45.3%) whose donor tested positive to
serum antibody against the hepatitis B core antigen
(anti-HBc). There were 2 cases (1.0%) of fulminant hep-
atitis B.
Pretransplantation lamivudine therapy for active rep-
licators was not a routine protocol. Pretransplantation
lamivudine therapy was initiated in 55 patients
(27.1%). Forty (30.3%) of 136 pre-LT active replicators
underwent pretransplantation lamivudine therapy.
Overall, the mean duration of pretransplantation lami-
vudine therapy was 2.1  5.3 months (range, 0.5-27.5
months). There were 2 patients with breakthrough in-
fection, but no patients underwent pretransplantation
adefovir therapy.
The prophylactic infusion of human HBV-speciﬁc
hepatitis B immunoglobulin (HBIG, anti–hepatitis B
immunoglobulin, Greencross, Korea) was administered
intravenously to all patients after LT (Fig. 1). HBIG was
initiated at the time of transplantation and was contin-
ued indeﬁnitely. HBIG was administered at 10,000-
20,000 IU during the anhepatic phase and 10,000 IU
daily for 7 days, followed by 10,000 IU weekly for the
ﬁrst month. Thereafter, the HBIG load was measured in
order to maintain the anti-HBs titers at 350 IU/L for
combination therapy with lamivudine, or the HBIG
dose was ﬁxed at 10,000 IU for HBIG monotherapy
every month for the ﬁrst year. After then, the HBIG dose
TABLE 1. Clinical Features of 203 Hepatitis B Virus–Related Liver Disease Patients at Time of Transplantation
According to Posttransplantation Prophylactic Regimen
Characteristic
Total
(n  203)
HBIG group
(n  95)
Combination group
(n  108) P value
Gender (male: female) 162:41 80:15 82:26 0.163
Mean age (yr) (mean  SD) 46.9  8.0 46.6  7.5 47.3  8.4 0.690
Active replicator* 136 (67.0%) 63 (66.3%) 73 (67.6%) 1.000
HBeAg positivity 95 (46.8%) 39 (41.1%) 56 (51.9%) 0.253
HBV DNA
Positivity 80 (39.4%) 53 (55.8%) 43 (390.8%) 0.015
Titer (pg/dL) (mean  SD) 215.5  674.6 348.1  898.2 610.3  1,080.8 0.007
Donor anti-HBc positivity 92 (45.3%) 42 (44.2%) 50 (47.6%) 0.424
HCV coinfection 3 (1.5%) 2 (2.1%) 1 (0.9%) 0.600
HCC 85 (41.9%) 46 (48.4%) 39 (36.1%) 0.088
UNOS status 0.532
1 2 (1.0%) 0 2 (10.9%)
2A 49 (24.1%) 24 (25.3%) 25 (230.0%)
2B 114 (56.2%) 60 (63.1%) 74 (680.5%)
Pre-LT lamivudine therapy 55 (27.1%) 29 (31.2%) 26 (24.3%) 0.071
Duration (months) (mean  SD) 7.6  7.8 9.7  7.9 50.5  70.4 0.189
Abbreviations: HBIG, hepatitis B immunoglobulin; HBeAg, HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCV,
hepatitis C virus; HCC hepatocellular carcinoma; UNOS, United Network for Organ Sharing; LT, liver transplantation.
*HBeAg and/or HBV DNA positive recipients.
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was reduced every 4-8 weeks in order to maintain the
anti-HBs titers at 200 to 250 IU/L, and lamivudine
was discontinued in combination therapy.
Ninety-ﬁve patients (46.8%) did not receive lamivu-
dine and were treated with HBIG only after the liver
transplantation (HBIG monotherapy, HBIG group). One
hundred eight patients (53.2%) were treated with lami-
vudine combined with HBIG after the liver transplanta-
tion (HBIG and lamivudine combination therapy, com-
bination group) at a daily dose of 25-100 mg according
to renal function. The prophylactic regimen was deter-
mined according to guideline of the each center; Sam-
sung Medical Center used HBIG monotherapy, and the
other centers used combination therapy. Adefovir was
not provided as a primary treatment after transplanta-
tion in this study. Both the HBIG and combination
groups were comparable with regard to the pre-LT clin-
ical features (Table 1). However, the HBV DNA positivity
and titer were much different. HBV DNA positivity was
more frequent in the HBIG group (55.8%) than in the
combination group (39.8%) (P  0.015). HBV DNA titer
was higher in the HBIG group (305.5  848.7 pg/dL)
than in the combination group (35.6 88.9 pg/dL) (P
0.007).
A calcineurin inhibitor plus a corticosteroid-based
protocol was used as the immunosuppressive therapy.
Corticosteroids were gradually discontinued 12 months
after LT. Mycophenolate mofetil and basiliximab were
used as rescue therapy for any renal insufﬁciency or as
a primary therapy in selected patients.
Acute cellular rejection (ACR) was deﬁned by liver
biopsy.6 In the case of ACR, a 500-mg intravenous bo-
lus of methylprednisolone was administered for 1-3
days, followed by a rapidly tapered regimen of intrave-
nous corticosteroid within 5-7 days. Oral corticosteroid
was tapered within 3-6 months after treatment for ACR.
There was no single prescribed corticosteroid therapy
for life.
The recurrence of the HBV was deﬁned as the appear-
ance of the hepatitis B s antigen (HBsAg) in the serum
after LT.5,7 The post-LT anti-HBs titer and clinical data
were collected every month after surgery. HBsAg and
any breakthrough infection were routinely monitored in
any patient with an abnormal liver function test (LFT)
and in cases of a sudden decrease in the anti-HBs titer
under HBIG therapy, as well as 1 year after the trans-
plantation in both the HBIG and combination groups.
Any HB recurrence after LT was initially treated with
lamivudine in the HBIG group and in combination
group where the lamivudine had been discontinued. In
the case of lamivudine resistance, the lamivudine treat-
ment was switched to or combined with adefovir.
After LT, the patients were followed up for a mean
time of 28.3  13.1 months (range, 6.1-60.3 months).
The data were analyzed from the time of enrollment
(between January 1, 1999, and December 31, 2001)
until the study closure date (January 1, 2004) or death.
Statistical Analysis
Statistical analyses were performed by SPSS 10.0 sta-
tistical software (SPSS, Chicago, IL). The categorical
variables were compared by Fisher’s exact test. The
continuous variables were compared by nonparametric
Mann-Whitney U test. The variables were compared by
the proportional hazard regression analysis to deter-
mine the independent predictive factors for HB recur-
rence after LT. The variables reaching statistical signif-
icance by univariate analysis were then included for
multivariate analysis. P  0.05 was considered to be
statistically signiﬁcant. Continuous normally distrib-
uted variables are represented as means  SD.
RESULTS
The overall 1- and 3-year survival rates were 94.6% and
90.1%, respectively. Overall, HB relapsed in 10.3% of
these recipients (21 of 203) with a 3-year actuarial risk
of 13.2% (7 of 53). The mean interval to recurrence after
the transplantation was 16.3  9.4 months (range,
2-40 months). A sudden drop in the anti-HBs titer in-
dicated the recurrence of HB, irrespective of the LFT.
Two patients showed an abnormal LFT without any
changes in the anti-HBs titer.
There was no statistically signiﬁcant differences in
the post-LT HB recurrence according to the recipients’
gender (P  0.150), age (P  0.555), United Network for
Organ Sharing status (P  0.533), graft type (P 
0.214), pre-LT active replicator (P  0.223), pre-LT
HBeAg positivity (P  0.768), pre-LT HBV DNA positiv-
ity (P 0.115), pre-LT HBV DNA titer (P 0.934), donor
anti-HBc positivity (P 0.694), pre-LT HCC (P 0.238),
pre-LT lamivudine therapy (P  0.976), the duration of
pre-LT lamivudine therapy (P  0.109), types of post-LT
prophylaxis (P  0.292), and the duration of corticoste-
roid therapy (P  0.083). Corticosteroid pulse therapy
(P  0.000), the cumulative dose of corticosteroid (P 
0.002), the recurrence of the HCC (P  0.000), and
systemic chemotherapy against HCC recurrence (P 
0.0001) were associated with post-LT HB recurrence
(Table 2).
Thirty-eight (18.7%) of 203 patients experienced ACR
Figure 1. Hepatitis B prophylaxis using hepatitis B immuno-
globulin (HBIG) and lamivudine (LAM) after liver transplanta-
tion.
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and underwent corticosteroid pulse therapy at 4.0  4.7
months (range, 8 days to 16 months) after LT. No patient
underwent antibody therapy because ACR was well con-
trolled with corticosteroid therapy, except in one patient,
who underwent retransplantation. Eight (21.1%) of 38
patients who underwent corticosteroid pulse therapy ex-
perienced HB recurrence, and 13 (7.8%) of 165 patients
did not experience HB recurrence (P  0.000). The me-
dian time to HB recurrence was 15.7 months (range,
1.5-24.7 months) after corticosteroid pulse therapy.
TABLE 2. Univariate analysis for the risk factors associated with the recurrence of hepatitis B after liver
transplantation
Variable
Post-LT HB recurrence (%)
P valueYes No
Gender 0.150
Male 19 (11.7) 143 (88.3)
Female 2 (4.9) 39 (95.1)
Age; years (mean  SD) 47.0  7.8 46.9  8.0 0.555
UNOS status 0.533
1, 2A 4 (7.8) 47 (92.2)
2B, 3 17 (11.2) 135 (88.8)
Graft type 0.214
Partial 15 (10.0) 135 (90.0)
Whole 6 (11.3) 47 (88.7)
Pre-LT active replicator* 0.223
Yes 17 (12.5) 119 (87.5)
No 2 (4.1) 49 (95.9)
Pre-LT HBeAg positivity 0.768
Yes 12 (12.6) 83 (87.4)
No 9 (8.9) 93 (91.1)
Pre-LT HBV DNA positivity 0.115
Yes 12 (13.2) 79 (86.8)
No 5 (5.9) 80 (94.1)
Pre-LT HBV DNA titer; pg/mL (mean  SD) 161.3  260.8 103.0  503.1 0.934
Donor anti-HBc positivity 0.694
Yes 12 (13.0) 80 (87.0)
No 6 (8.8) 62 (91.2)
HCC 0.238
Yes 11 (12.9) 74 (87.1)
No 10 (8.5) 108 (91.5)
Pre-LT lamivudine therapy 0.976
Yes 5 (9.1) 50 (90.9)
No 15 (10.7) 125 (89.3)
Duration of pre-LT lamivudine therapy;
months (mean  SD)
1.27  0.46 1.36  0.53 0.109
Post-LT combination therapy 0.292
Yes 15 (13.8) 93 (86.2)
No 6 (6.3) 89 (93.7)
Corticosteroid pulse therapy 0
Yes 8 (21.1) 30 (78.9)
No 13 (7.8) 152 (92.2)
Duration of corticosteroid therapy; months
(mean  SD)
14.1  15.4 13.0  11.4 0.083
Cumulative dose of corticosteroid; mg (mean
 SD)
3,824.6  2,021.3 2,847.9  1,143.4 0.002
HCC recurrence 0.000
Yes 5 (31.3) 11 (68.8)
No 16 (8.6) 171 (91.4)
Systemic chemotherapy against HCC
recurrence
0.000
Yes 5 (38.5) 8 (61.5)
No 16 (8.4) 174 (91.6)
Abbreviations: LT, liver transplantation; HB, hepatitis B; HBV, hepatitis B virus; UNOS, United Network for Organ Sharing;
HCC, hepatocellular carcinoma.
*HBeAg and/or HBV DNA positive recipients.
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The mean duration of corticosteroid therapy was
13.1  11.8 months, and cumulative corticosteroid
dose was 2,942.1  1,278.1 mg. There were no differ-
ences in the duration of corticosteroid therapy between
the patients with HB recurrence (14.1  15.4 months)
and without recurrence (13.0  11.4 months) (P 
0.083). However, the mean cumulative corticosteroid
dose was higher in the patients with HB recurrence
(3,824.6  2,021.3 mg) than in those without recur-
rence (2,847.9  1,143.4 mg) (P  0.002).
Pretransplantation HCC itself was not associated
with posttransplantation HB recurrence (P  0.238).
HCC recurrence was detected in 16 (7.9%) of 203 pa-
tients at 6.9  9.1 months (range, 1.8-38.8 months).
HCC recurrence had a marked effect on HB recurrence.
HB recurred in 5 (31.3%) of 16 patients in whom HCC
had recurred and in 16 (8.6%) of 171 patients in whom
HCC did not (P  0).
Treatment against HCC recurrence was begun at
7.1  9.0 months (range, 2.0-39.7 months) after trans-
plantation. Of the 16 patients with HCC recurrence, 13
patients (81.3%) received 5-ﬂuorouracil–based sys-
temic chemotherapy, 7 patients (43.8%) received radi-
ation therapy, 6 patients (37.5%) received transhepatic
arterial chemoembolization, and 5 patients (31.3%) un-
derwent surgery. Ten of 16 patients underwent multi-
modality combination therapy. Systemic chemotherapy
had a marked effect on HB recurrence. HB recurred in
5 (38.5%) of 13 posttransplantation systemic HCC
treatment and in 15 (7.9%) of the other 190 patients
(P  0.000). However, no one experienced HB recur-
rence after locoregional treatment modality only, such
as surgery, transarterial chemoembolization, or radia-
tion therapy. The median time interval between sys-
temic chemotherapy and HB recurrence was 5.2
months (range, 3.5-9.6 months).
Multivariate analysis revealed the cumulative dose of
corticosteroid (P  0.000, hazard ratio 19.596; 95% CI,
3.903-98.382) and systemic therapy against HCC re-
currence (P  0.001, hazard ratio 12.775; 95% CI,
2.900-56.269) to be statistically signiﬁcantly associ-
ated with HB recurrence after liver transplantation,
which conﬁrms its independent predictive value in this
setting.
The rate of HB recurrence between the HBIG group
(6.3%) and combination group (13.8%) was similar (P 
0.292). Table 3 shows the risk factors for HB recurrence
in both groups. There were no differences in corticoste-
roid pulse therapy (P  0.390), HCC recurrence (P 
0.156), and systemic chemotherapy (P  0.579) be-
tween the 2 groups. However, the duration of cortico-
steroid therapy (P  0.038) and the cumulative cortico-
steroid dose (P  0.003) were higher in the HBIG group
than in the combination group, which was probably the
result of differences in the corticosteroid tapering pro-
tocol used at each center.
In the 21 patients who experienced HB recurrence,
lamivudine was administered to 6 patients, who were
treated with HBIG monotherapy, and in 12 patients,
who were treated with combination therapy, although
the lamivudine had been discontinued. The other 3
patients were given combination therapy with no addi-
tional treatment. Two of these 3 patients had HB recur-
rence at 8 months and at 9 months after LT while
receiving chemotherapy for systemic metastasis of the
HCC, respectively. These patients died of metastasis 15
months and 13 months after transplantation, respec-
tively. The third patient developed sepsis associated
with biliary leakage 2 months after LT and experienced
HB recurrence 7 months after LT. This patient died of
multiorgan failure associated with biliary sepsis 10
months after transplantation.
None of the patients who experienced HB recurrence
required adefovir as ﬁrst-line therapy. Two of the pa-
tients who experienced HB recurrence were switched to
adefovir therapy because of the presence of lamivudine-
resistant mutants 12 and 14 months after lamivudine
therapy, respectively.
The outcome of HB recurrence varied. Two (9.5%) of
21 HB recurrences experienced hepatic failure; one pa-
tient died, and the other underwent retransplantation
but died of graft failure from an unknown origin. Four
(19.5%) of these 21 patients showed an abnormal LFT;
2 of these 4 patients were switched to adefovir because
of the presence of lamivudine-resistant mutants. The
other patients (71.4%) responded well to lamivudine
therapy and had a normal LFT.
DISCUSSION
The ideal regimen in the era of HBIG and lamivudine
has not been identiﬁed until now.8,9 The mechanism by
TABLE 3. Comparison of Risk Factors Associated With Recurrence of Hepatitis B After Liver Transplantation
According to
Variable
HBIG group
(n  95)
Combination group
(n  108) P-value
Corticosteroid pulse therapy 22 (23.2%) 16 (14.8%) 0.390
Duration of corticosteroid therapy; month (mean  SD) 16.1  13.7 10.2  8.8 0.038
Cumulative dose of corticosteroid; mg (mean  SD) 3,195.3  1,473.3 2,740.1  1,064.7 0.003
HCC recurrence 6 (6.3%) 10 (9.3%) 0.156
Systemic chemotherapy against HCC recurrence 5 (5.3%) 8 (7.4%) 0.579
Abbreviations: HBIG, hepatitis B immunoglobulin; HCC, hepatocellular carcinoma.
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which HBIG prevents graft reinfection is unclear. HBIG
may decrease the horizontal spread of an HBV infection
within the liver by neutralizing the circulating virus
particles and inducing the lysis of infected hepatocytes
through a pathway such as antibody-dependent cellu-
lar cytotoxicity. The reduction of the circulating virions
by HBIG may decrease the viral substrate available to
lamivudine and decrease the emergence of drug-resis-
tant mutants. On the other hand, the decrease in the
virus load induced by lamivudine may prevent the sat-
uration of the HBIG binding sites and reduce the im-
mune pressure leading to the emergence of surface
gene mutations. Therefore, the combined HBIG and
lamivudine therapy might offer synergistic protection
against graft reinfection, and the combination appears
to be more effective than single-agent prophylaxis.10 A
guideline of HBV prophylaxis in an LT setting based on
a European and an American perspective was provided.
This involves the use of lamivudine or adefovir before
LT, followed by combination therapy. This protocol pro-
vides improved control of virus replication before LT
and complimentary forms of prophylaxis after LT to
minimize the risk of reinfection. With this combination
approach, the HB recurrence rate at 1-2 years after LT
has been reduced to 10%.8 In this study, the overall
HB recurrence rate was 10.3%, which was comparable
to other studies,3-5,7-9 and there was no difference in
the rates of HB recurrence between the HBIG group and
combination group.
In this study, lamivudine was withdrawn at the end of
the ﬁrst postoperative year in the combination therapy.
Prolonged lamivudine therapy in the posttransplanta-
tion setting can lead to the development of lamivudine-
resistant mutants and may need high cost.11 In addi-
tion, there is no prospective randomized study that has
assessed whether post-LT long-term lamivudine ther-
apy (1 year vs.  1 year) with HBIG reduces HB recur-
rence. HBsAg, HBeAg, and HBV DNA were routinely
checked 1 year after transplantation, and then lamivu-
dine was stopped in the patients with negative serologic
test with well-maintained LFT and anti-HBs titers in the
combination group. Two (1.0%) of 203 patients showed
positive HBV DNA 1 year later. They had negative
1-year HBsAg and HBeAg, and a good LFT, and anti-
HBs titer was well maintained. We did not prescribe
additional therapy because the signiﬁcance of serum
HBV DNA positivity in the absence of circulating HBsAg
is uncertain.12 Liver biopsy was carried out at 16 and
36 months after transplantation in one patient and at
38 months in the other. There were no lobular activities
or portal ﬁbrosis. The patients were followed up for 76
and 64months and had no clinically relevant problems.
Until now, the factors associated with a lower inci-
dence of HB recurrence were reported to be a negative
the HBeAg and serumHBVDNA before LT, a hepatitis D
virus superinfection, and fulminant hepatitis B.1,2-4,7
Lamivudine resistance and a high HBV DNA load at the
time of LT is associated with an increased risk of HB
recurrence after receiving a liver transplant.5 Therefore,
pretransplantation lamivudine therapy is used to sup-
press HBV replication by achieving a loss of HBV DNA
in 60-100% after 2-3 months of therapy.13-15 However,
pretransplantation lamivudine therapy has several dis-
advantages. Long-term lamivudine therapy is expen-
sive, and its use results in the development of lamivu-
dine-resistant mutations, which are one of the major
risk factors of posttransplantation HB recurrence. In
addition, there has been no prospective randomized
study to prove the efﬁcacy of pretransplantation lami-
vudine therapy on posttransplantation HB recur-
rence.16 Pretransplantation lamivudine therapy was
not a routine protocol in this study.
We did not clarify the role of pretransplantation active
replicators on the posttransplantation HB recurrence
because this study was a retrospective review and HBV
DNA was monitored by an assay with detection limit of
5 log. However, the results of this study also suggested
a role of the pre-LT virus load in post-LT HB recurrence.
Seven of the 8 patients in this study who had experi-
enced HB recurrence after corticosteroid pulse therapy
had pre-LT active replicators. None of the pre-LT non-
replicators who underwent corticosteroid pulse therapy
experienced HB recurrence. It appeared that pre-LT
active virus replication had an effect on HB recurrence
in patients with massive immunosuppression.
In addition, it is well known the serum anti-HBc pos-
itivity in donors is a marker for the risk of HBV trans-
mission and reactivation after LT in HBsAg-negative
naive patients.17-20 In Korea, which has a persistent
organ donor scarcity, an anti-HBc–positive donor liver
cannot be avoided,19-23 and it had no effect on the
posttransplantation HB recurrence when an appropri-
ate prophylactic regimen was in place.
This study shows that HB recurrence after LT was
related to corticosteroid pulse therapy and cumulative
corticosteroid dose. HB recurrence was detected in 8
(21.1%) of 38 ACR cases. The interaction between cor-
ticosteroid pulse therapy and HB recurrence is unclear
but can be explained as follows. The HBV has a corti-
costeroid receptor that promotes virus replication.
Moreover, immunosuppressive therapy itself reacti-
vates HBV replication. The increased totality of immu-
nosuppression, particularly because corticosteroid
pulse therapy in the early phase after LT can participate
in HB recurrence but a long duration of low-dose cor-
ticosteroid therapy itself cannot. The mechanism for
how early corticosteroid pulse therapy affects the late
onset of HB recurrence is unclear but can be explained
as follows: Massive immunosuppression with cortico-
steroid pulse therapy allows virus replication with a
consequent increase in hepatocyte infection. However,
in the early post-LT period, high-dose HBIG reduces the
serum HBsAg to less than the detection level. At the
same time, maintenance immunosuppressive therapy
may delay or mask the destruction of the infected hepa-
tocytes. The withdrawal or tapering of these HBV pro-
phylactic drugs results in HBV expression in the serum
to reach detection level. Moreover, the partial restora-
tion of immunocompetence leads to the rapid destruc-
tion of the infected hepatocytes.
Because an increased cumulative dose of corticoste-
roid as a consequence of corticosteroid pulse therapy
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can be a risk factor for HB recurrence after LT, care
should be taken when deciding the appropriate treat-
ment for ACR. The histopathological diagnosis of ACR
may not automatically signal that a treatment is indi-
cated, particularly if it is low grade. Because ACR is less
frequent in living donor LT,24 it is more often affected by
more than one condition, such as preservation-related
problems or vascular or biliary tree problems, which are
widely considered to be completely reversible phenom-
ena.6
Multivariate analysis showed that systemic chemo-
therapy against the recurrence of HCC also had an
effect on HB recurrence, even though all patients with
HCC recurrence continued to receive prophylactic ther-
apy against HBV and their prechemotherapy LFT and
anti-HBs titer were well maintained. A recurrence of
HCC was noted in 16 patients at the following sites:
liver (n  5), bone (n  4), lung (n  3), peritoneum (n 
2), lymph nodes (n  2), spleen (n  1), and adrenal
glands (n 1). Thirteen of these 16 recipients died from
progression of HCC. HB recurred in 5 (31.3%) of 16
recipients in whom HCC recurred. These 5 patients
experienced HB recurrence after systemic chemother-
apy against HCC recurrence. It is well documented that
cytotoxic treatment in patients carrying HBV enhances
the risk of severe hepatic damage25-28 as a result of the
breakthrough of the host immune barrier by means of
cytotoxic chemotherapy. However, the validity of this
correlation has not been established in clinical trials
with a LT setting for HB, particularly under adequate
HB prophylaxis. The median duration between sys-
temic chemotherapy and HB recurrence (5.2 months)
was shorter than that between corticosteroid pulse
therapy and HB recurrence (15.7 months). It is possible
that HCC recurrence itself is a product of any break-
through of the host immunity, and active cell prolifer-
ation in a malignant transformation can induce active
replication of the HBV in the liver.29 This complexity of
the mechanism of cytotoxic systemic chemotherapy
may affect HB recurrence. We had been unaware that
systemic chemotherapy could be a risk factor for the
recurrence of HB in patients receiving routine antiviral
prophylaxis after LT. For this reason, the prophylactic
protocol against the HBV was not changed in those
patients. However, we now recommend more intensive
monitoring and antiviral prophylaxis in those patients.
The natural course of a recurrent HB infection under
immunosuppression after liver transplantation is
much more aggressive than in nonimmunosuppressed
patients. However, the treatment for recurrent HB in
liver transplant recipients is now much less of a clinical
problem than before.8 The optimal therapy for those
HB-infected liver transplant recipients depends on the
treatments previously received. A rapid reduction in
immunosuppressive therapy is a common practice, and
effective antiviral therapy is essential for preventing
disease progression.8
In conclusion, despite the limitations of this retro-
spective analysis, this study showed that LT for HBV-
related liver disease was safe and associated with low
recurrence rates if adequate prophylaxis was provided.
However, the cumulative corticosteroid dose and sys-
temic chemotherapy against the recurrence of HCC had
an effect on HB recurrence under an adequate prophy-
lactic regimen. Therefore, physicians must be aware of
this problem, monitor for HB recurrence, and consider
additional powerful prophylaxis against HBV in these
patients.
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